TG Therapeutics, Inc. (TGTX) looks forward to a strong close to 2024, with significant progress expected in both its commercial and clinical pipeline heading into 2025.
TG Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of multiple sclerosis (MS) and blood cancers.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com